ReviewACS nano2018
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.
Review in ACS nano, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.Advanced drug delivery reviews · 2020Pooled it
- Folate-targeted gold nanoparticles for doxorubicin delivery in tumor spheroids.Drug delivery · 2026Article
- Evaluation ofACS omega · 2026Article
- CuO stabilized on magnetic decorated GO nanosheets for efficient synthesis of 3,4-dihydropyrimidine-2(1H)-one/thione and 1,4-dihydropyridine derivatives under green conditions.Scientific reports · 2026Article
- Rational engineering of cholesterol-modified prodrug nanoassemblies for improving the tumor selectivity and safety of mitoxantrone.Fundamental research · 2026Article
- The landscape of nanomedical clinical trials.Nano today · 2026Article
- Predicting the Dominant Role of Dense Aggregates in Magnetic Hyperthermia via Intracellular-Mimetic Nanoparticle Models.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies.Discover oncology · 2025Review
- Nano-oncology revisited: Insights on precise therapeutic advances and challenges in tumor.Fundamental research · 2025Review
- Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025Review
- NSAID-encapsulated nanoparticles as a targeted therapeutic platform for modulating chronic inflammation and inhibiting cancer progression: a review.Inflammopharmacology · 2025Review
- Innovative approach to the detection of circulating tumor biomarkers: multi-dimensional application of liposome technology.Lipids in health and disease · 2025Review
- Current Trends and Advances in Nanoplatforms-Based Imaging for Cancer Diagnosis.Indian journal of microbiology · 2025Article
- Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy.ACS measurement science au · 2025Review
- Dietary Fiber and Cancer Management: A Twenty-Five-Year Bibliometric Review of Research Trends and Directions.BioMed research international · 2025Review
- How Advanced are Self-Assembled Nanomaterials for Targeted Drug Delivery? A Comprehensive Review of the Literature.International journal of nanomedicine · 2025Review
- Recent Insights into Nanotechnology in Colorectal Cancer.Applied biochemistry and biotechnology · 2024Review
- Biomedical applications of graphene-based nanomaterials: recent progress, challenges, and prospects in highly sensitive biosensors.Discover nano · 2024Review
- New insights into targeted therapy of glioblastoma using smart nanoparticles.Cancer cell international · 2024Review
- In vivo imaging using surface enhanced spatially offset raman spectroscopy (SESORS): balancing sampling frequency to improve overall image acquisition.Npj imaging · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Ongoing research into the application of nanotechnology for cancer treatment and diagnosis has demonstrated its advantages within contemporary oncology as well as its intrinsic limitations. The National Cancer Institute publishes the Cancer Nanotechnology Plan every 5 years since 2005. The most recent iteration helped codify the ongoing basic and translational efforts of the field and displayed its breadth with several evolving areas. From merely a technological perspective, this field has seen tremendous growth and success. However, an incomplete understanding of human cancer biology persists relative to the application of nanoscale materials within contemporary oncology. As such, this review presents several evolving areas in cancer nanotechnology in order to identify key clinical and biological challenges that need to be addressed to improve patient outcomes. From this clinical perspective, a sampling of the nano-enabled solutions attempting to overcome barriers faced by traditional therapeutics and diagnostics in the clinical setting are discussed. Finally, a strategic outlook of the future is discussed to highlight the need for next-generation cancer nanotechnology tools designed to address critical gaps in clinical cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.